Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease

Fibrogenesis and Tissue Repair

Volumn 5, Issue 1, 2012, Pages

  Fan, Dong ^a   Takawale, Abhijit ^a   Lee, Jiwon ^a   Kassiri, Zamaneh ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Cardiac fibroblast; Extracellular matrix remodeling; Heart disease; Matrix metalloproteinases; Tissue inhibitor of metalloproteinases

Indexed keywords

COLLAGENASE 3; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 28; NEUTROPHIL COLLAGENASE; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TISSUE INHIBITOR OF METALLOPROTEINASE 4; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; CARDIAC FIBROBLAST; CELL FUNCTION; DISEASE COURSE; DISEASE MODEL; EXTRACELLULAR MATRIX; FIBROBLAST; HEART DISEASE; HEART MUSCLE FIBROSIS; HEART STRESS; HOMEOSTASIS; HUMAN; HYPERTENSION; HYPERTROPHIC CARDIOMYOPATHY; MESENCHYME CELL; MYOFIBROBLAST; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; UNSTABLE ANGINA PECTORIS;

EID: 84866342680     PISSN: None     EISSN: 17551536     Source Type: Journal    
DOI: 10.1186/1755-1536-5-15     Document Type: Review

References (148)

1. Camelliti P, Borg TK, Kohl P. Structural and functional characterisation of cardiac fibroblasts. Cardiovasc Res 2005, 65:40-51. 10.1016/j.cardiores.2004.08.020, 15621032.
2. Souders CA, Bowers SL, Baudino TA. Cardiac fibroblast: the renaissance cell. Circ Res 2009, 105:1164-1176. 10.1161/CIRCRESAHA.109.209809, 3345531, 19959782.
3. Hill JA, Olson EN. Cardiac plasticity. N Engl J Med 2008, 358:1370-1380. 10.1056/NEJMra072139, 18367740.
4. Koitabashi N, Kass DA. Reverse remodeling in heart failure - mechanisms and therapeutic opportunities. Nat Rev Cardiol 2012, 9:147-157.
5. Kranias EG, Hajjar RJ. Modulation of cardiac contractility by the phopholamban/SERCA2a regulatome. Circ Res 2012, 110:1646-1660. 10.1161/CIRCRESAHA.111.259754, 22679139.
6. Krenning G, Zeisberg EM, Kalluri R. The origin of fibroblasts and mechanism of cardiac fibrosis. J Cell Physiol 2010, 225:631-637. 10.1002/jcp.22322, 3098503, 20635395.
7. Fries KM, Blieden T, Looney RJ, Sempowski GD, Silvera MR, Willis RA, Phipps RP. Evidence of fibroblast heterogeneity and the role of fibroblast subpopulations in fibrosis. Clin Immunol Immunopathol 1994, 72:283-292. 10.1006/clin.1994.1144, 7914840.
8. Franke WW, Schmid E, Osborn M, Weber K. Intermediate-sized filaments of human endothelial cells. J Cell Biol 1979, 81:570-580. 10.1083/jcb.81.3.570, 2110384, 379021.
9. Mork C, van Deurs B, Petersen OW. Regulation of vimentin expression in cultured human mammary epithelial cells. Differentiation 1990, 43:146-156. 10.1111/j.1432-0436.1990.tb00441.x, 2373288.
10. Camelliti P, Green CR, LeGrice I, Kohl P. Fibroblast network in rabbit sinoatrial node: structural and functional identification of homogeneous and heterogeneous cell coupling. Circ Res 2004, 94:828-835. 10.1161/01.RES.0000122382.19400.14, 14976125.
11. Goldsmith EC, Hoffman A, Morales MO, Potts JD, Price RL, McFadden A, Rice M, Borg TK. Organization of fibroblasts in the heart. Dev Dyn 2004, 230:787-794. 10.1002/dvdy.20095, 15254913.
12. Shrivastava A, Radziejewski C, Campbell E, Kovac L, McGlynn M, Ryan TE, Davis S, Goldfarb MP, Glass DJ, Lemke G, Yancopoulos GD. An orphan receptor tyrosine kinase family whose members serve as nonintegrin collagen receptors. Mol Cell 1997, 1:25-34. 10.1016/S1097-2765(00)80004-0, 9659900.
13. Vogel W, Gish GD, Alves F, Pawson T. The discoidin domain receptor tyrosine kinases are activated by collagen. Mol Cell 1997, 1:13-23. 10.1016/S1097-2765(00)80003-9, 9659899.
14. Schlessinger J. Direct binding and activation of receptor tyrosine kinases by collagen. Cell 1997, 91:869-872. 10.1016/S0092-8674(00)80477-8, 9428509.
15. Alves F, Vogel W, Mossie K, Millauer B, Hofler H, Ullrich A. Distinct structural characteristics of discoidin I subfamily receptor tyrosine kinases and complementary expression in human cancer. Oncogene 1995, 10:609-618.
16. Lai C, Lemke G. An extended family of protein-tyrosine kinase genes differentially expressed in the vertebrate nervous system. Neuron 1991, 6:691-704. 10.1016/0896-6273(91)90167-X, 2025425.
17. Ebihara Y, Masuya M, Larue AC, Fleming PA, Visconti RP, Minamiguchi H, Drake CJ, Ogawa M. Hematopoietic origins of fibroblasts: II. In vitro studies of fibroblasts, CFU-F, and fibrocytes. Exp Hematol 2006, 34:219-229. 10.1016/j.exphem.2005.10.008, 16459190.
18. Shyu KG, Chao YM, Wang BW, Kuan P. Regulation of discoidin domain receptor 2 by cyclic mechanical stretch in cultured rat vascular smooth muscle cells. Hypertension 2005, 46:614-621. 10.1161/01.HYP.0000175811.79863.e2, 16087782.
19. Ferri N, Carragher NO, Raines EW. Role of discoidin domain receptors 1 and 2 in human smooth muscle cell-mediated collagen remodeling: potential implications in atherosclerosis and lymphangioleiomyomatosis. Am J Pathol 2004, 164:1575-1585. 10.1016/S0002-9440(10)63716-9, 1615659, 15111304.
20. Mohan RR, Wilson SE. Discoidin domain receptor (DDR) 1 and 2: collagen-activated tyrosine kinase receptors in the cornea. Exp Eye Res 2001, 72:87-92. 10.1006/exer.2000.0932, 11133186.
21. Strutz F, Okada H, Lo CW, Danoff T, Carone RL, Tomaszewski JE, Neilson EG. Identification and characterization of a fibroblast marker: FSP1. J Cell Biol 1995, 130:393-405. 10.1083/jcb.130.2.393, 2199940, 7615639.
22. Mazzucchelli L. Protein S100A4: too long overlooked by pathologists?. Am J Pathol 2002, 160:7-13. 10.1016/S0002-9440(10)64342-8, 1867142, 11786392.
23. Petrov VV, Fagard RH, Lijnen PJ. Stimulation of collagen production by transforming growth factor-beta1 during differentiation of cardiac fibroblasts to myofibroblasts. Hypertension 2002, 39:258-263. 10.1161/hy0202.103268, 11847194.
24. Gabbiani G, Ryan GB, Majne G. Presence of modified fibroblasts in granulation tissue and their possible role in wound contraction. Experientia 1971, 27:549-550. 10.1007/BF02147594, 5132594.
25. Baum J, Duffy HS. Fibroblasts and myofibroblasts: what are we talking about?. J Cardiovasc Pharmacol 2011, 57:376-379. 10.1097/FJC.0b013e3182116e39, 3077448, 21297493.
26. Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol 2002, 3:349-363. 10.1038/nrm809, 11988769.
27. Santiago JJ, Dangerfield AL, Rattan SG, Bathe KL, Cunnington RH, Raizman JE, Bedosky KM, Freed DH, Kardami E, Dixon IM. Cardiac fibroblast to myofibroblast differentiation in vivo and in vitro: expression of focal adhesion components in neonatal and adult rat ventricular myofibroblasts. Dev Dyn 2010, 239:1573-1584. 10.1002/dvdy.22280, 20503355.
28. Gabbiani G. The myofibroblast in wound healing and fibrocontractive diseases. J Pathol 2003, 200:500-503. 10.1002/path.1427, 12845617.
29. Calderone A, Bel-Hadj S, Drapeau J, El-Helou V, Gosselin H, Clement R, Villeneuve L. Scar myofibroblasts of the infarcted rat heart express natriuretic peptides. J Cell Physiol 2006, 207:165-173. 10.1002/jcp.20548, 16270351.
30. Tamaoki M, Imanaka-Yoshida K, Yokoyama K, Nishioka T, Inada H, Hiroe M, Sakakura T, Yoshida T. Tenascin-C regulates recruitment of myofibroblasts during tissue repair after myocardial injury. Am J Pathol 2005, 167:71-80. 10.1016/S0002-9440(10)62954-9, 1603439, 15972953.
31. Walker GA, Masters KS, Shah DN, Anseth KS, Leinwand LA. Valvular myofibroblast activation by transforming growth factor-beta: implications for pathological extracellular matrix remodeling in heart valve disease. Circ Res 2004, 95:253-260. 10.1161/01.RES.0000136520.07995.aa, 15217906.
32. Lie-Venema H, van den Akker NM, Bax NA, Winter EM, Maas S, Kekarainen T, Hoeben RC, de Ruiter MC, Poelmann RE, Gittenberger-de Groot AC. Origin, fate, and function of epicardium-derived cells (EPDCs) in normal and abnormal cardiac development. ScientificWorldJournal 2007, 7:1777-1798.
33. Norris RA, Borg TK, Butcher JT, Baudino TA, Banerjee I, Markwald RR. Neonatal and adult cardiovascular pathophysiological remodeling and repair: developmental role of periostin. Ann N Y Acad Sci 2008, 1123:30-40. 10.1196/annals.1420.005, 18375575.
34. Olivey HE, Mundell NA, Austin AF, Barnett JV. Transforming growth factor-beta stimulates epithelial-mesenchymal transformation in the proepicardium. Dev Dyn 2006, 235:50-59. 10.1002/dvdy.20593, 3160345, 16245329.
35. Gittenberger-de Groot AC, Vrancken Peeters MP, Mentink MM, Gourdie RG, Poelmann RE. Epicardium-derived cells contribute a novel population to the myocardial wall and the atrioventricular cushions. Circ Res 1998, 82:1043-1052. 10.1161/01.RES.82.10.1043, 9622157.
36. Kolditz DP, Wijffels MC, Blom NA, van der Laarse A, Hahurij ND, Lie-Venema H, Markwald RR, Poelmann RE, Schalij MJ, Gittenberger-de Groot AC. Epicardium-derived cells in development of annulus fibrosis and persistence of accessory pathways. Circulation 2008, 117:1508-1517. 10.1161/CIRCULATIONAHA.107.726315, 18332266.
37. Zhou B, von Gise A, Ma Q, Hu YW, Pu WT. Genetic fate mapping demonstrates contribution of epicardium-derived cells to the annulus fibrosis of the mammalian heart. Dev Biol 2010, 338:251-261. 10.1016/j.ydbio.2009.12.007, 2815244, 20025864.
38. de Lange FJ, Moorman AF, Anderson RH, Manner J, Soufan AT, de Gier-de Vries C, Schneider MD, Webb S, van den Hoff MJ, Christoffels VM. Lineage and morphogenetic analysis of the cardiac valves. Circ Res 2004, 95:645-654. 10.1161/01.RES.0000141429.13560.cb, 15297379.
39. Lucas JA, Zhang Y, Li P, Gong K, Miller AP, Hassan E, Hage F, Xing D, Wells B, Oparil S, Chen YF. Inhibition of transforming growth factor-beta signaling induces left ventricular dilation and dysfunction in the pressure-overloaded heart. Am J Physiol Heart Circ Physiol 2010, 298:H424-H432. 10.1152/ajpheart.00529.2009, 2822586, 19933419.
40. Zeisberg EM, Tarnavski O, Zeisberg M, Dorfman AL, McMullen JR, Gustafsson E, Chandraker A, Yuan X, Pu WT, Roberts AB, Neilson EG, Sayegh MH, Isumo S, Kalluri R. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med 2007, 13:952-961. 10.1038/nm1613, 17660828.
41. Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med 2012, 18:1028-1040. 10.1038/nm.2807, 22772564.
42. Garcia J, Sandi MJ, Cordelier P, Binetruy B, Pouyssegur J, Iovanna JL, Tournaire R. Tie1 deficiency induces endothelial-mesenchymal transition. EMBO Rep 2012, 13:431-439. 10.1038/embor.2012.29, 22421998.
43. Russell JL, Goetsch SC, Gaiano NR, Hill JA, Olson EN, Schneider JW. A dynamic notch injury response activates epicardium and contributes to fibrosis repair. Circ Res 2011, 108:51-59. 10.1161/CIRCRESAHA.110.233262, 3042596, 21106942.
44. Haudek SB, Xia Y, Huebener P, Lee JM, Carlson S, Crawford JR, Pilling D, Gomer RH, Trial J, Frangogiannis NG, Entman ML. Bone marrow-derived fibroblast precursors mediate ischemic cardiomyopathy in mice. Proc Natl Acad Sci U S A 2006, 103:18284-18289. 10.1073/pnas.0608799103, 1643845, 17114286.
45. van Amerongen MJ, Bou-Gharios G, Popa E, van Ark J, Petersen AH, van Dam GM, van Luyn MJ, Harmsen MC. Bone marrow-derived myofibroblasts contribute functionally to scar formation after myocardial infarction. J Pathol 2008, 214:377-386. 10.1002/path.2281, 18095257.
46. van Amerongen MJ, Harmsen MC, van Rooijen N, Petersen AH, van Luyn MJ. Macrophage depletion impairs wound healing and increases left ventricular remodeling after myocardial injury in mice. Am J Pathol 2007, 170:818-829. 10.2353/ajpath.2007.060547, 1864893, 17322368.
47. Ogawa M, LaRue AC, Drake CJ. Hematopoietic origin of fibroblasts/myofibroblasts: Its pathophysiologic implications. Blood 2006, 108:2893-2896. 10.1182/blood-2006-04-016600, 16840726.
48. Mollmann H, Nef HM, Kostin S, von Kalle C, Pilz I, Weber M, Schaper J, Hamm CW, Elsasser A. Bone marrow-derived cells contribute to infarct remodelling. Cardiovasc Res 2006, 71:661-671. 10.1016/j.cardiores.2006.06.013, 16854401.
49. Kania G, Blyszczuk P, Stein S, Valaperti A, Germano D, Dirnhofer S, Hunziker L, Matter CM, Eriksson U. Heart-infiltrating prominin-1+/CD133+ progenitor cells represent the cellular source of transforming growth factor beta-mediated cardiac fibrosis in experimental autoimmune myocarditis. Circ Res 2009, 105:462-470. 10.1161/CIRCRESAHA.109.196287, 19628793.
50. Xu J, Lin SC, Chen J, Miao Y, Taffet GE, Entman ML, Wang Y. CCR2 mediates the uptake of bone marrow-derived fibroblast precursors in angiotensin II-induced cardiac fibrosis. Am J Physiol Heart Circ Physiol 2011, 301:H538-H547. 10.1152/ajpheart.01114.2010, 3154672, 21572015.
51. Humphreys BD, Lin SL, Kobayashi A, Hudson TE, Nowlin BT, Bonventre JV, Valerius MT, McMahon AP, Duffield JS. Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol 2010, 176:85-97. 10.2353/ajpath.2010.090517, 2797872, 20008127.
52. Covas DT, Panepucci RA, Fontes AM, Silva WA, Orellana MD, Freitas MC, Neder L, Santos AR, Peres LC, Jamur MC, Zago MA. Multipotent mesenchymal stromal cells obtained from diverse human tissues share functional properties and gene-expression profile with CD146+ perivascular cells and fibroblasts. Exp Hematol 2008, 36:642-654. 10.1016/j.exphem.2007.12.015, 18295964.
53. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126:663-676. 10.1016/j.cell.2006.07.024, 16904174.
54. Tapscott SJ, Davis RL, Thayer MJ, Cheng PF, Weintraub H, Lassar AB. MyoD1: a nuclear phosphoprotein requiring a Myc homology region to convert fibroblasts to myoblasts. Science 1988, 242:405-411. 10.1126/science.3175662, 3175662.
55. Vierbuchen T, Ostermeier A, Pang ZP, Kokubu Y, Sudhof TC, Wernig M. Direct conversion of fibroblasts to functional neurons by defined factors. Nature 2010, 463:1035-1041. 10.1038/nature08797, 2829121, 20107439.
56. Song K, Nam YJ, Luo X, Qi X, Tan W, Huang GN, Acharya A, Smith CL, Tallquist MD, Neilson EG, Hill JA, Bassel-Duby R, Olson EN. Heart repair by reprogramming non-myocytes with cardiac transcription factors. Nature 2012, 485:599-604. 10.1038/nature11139, 22660318.
57. Ieda M, Fu JD, Delgado-Olguin P, Vedantham V, Hayashi Y, Bruneau BG, Srivastava D. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell 2010, 142:375-386. 10.1016/j.cell.2010.07.002, 2919844, 20691899.
58. Jayawardena TM, Egemnazarov B, Finch EA, Zhang L, Payne JA, Pandya K, Zhang Z, Rosenberg P, Mirotsou M, Dzau VJ. MicroRNA-mediated in vitro and in vivo direct reprogramming of cardiac fibroblasts to cardiomyocytes. Circ Res 2012, 110:1465-1473. 10.1161/CIRCRESAHA.112.269035, 22539765.
59. Kohl P. Heterogeneous cell coupling in the heart: an electrophysiological role for fibroblasts. Circ Res 2003, 93:381-383. 10.1161/01.RES.0000091364.90121.0C, 12958139.
60. Gaudesius G, Miragoli M, Thomas SP, Rohr S. Coupling of cardiac electrical activity over extended distances by fibroblasts of cardiac origin. Circ Res 2003, 93:421-428. 10.1161/01.RES.0000089258.40661.0C, 12893743.
61. Porter KE, Turner NA. Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol Ther 2009, 123:255-278. 10.1016/j.pharmthera.2009.05.002, 19460403.
62. Eghbali M. Cardiac fibroblasts: function, regulation of gene expression, and phenotypic modulation. Basic Res Cardiol 1992, 87(Suppl 2):183-189.
63. Butt RP, Laurent GJ, Bishop JE. Collagen production and replication by cardiac fibroblasts is enhanced in response to diverse classes of growth factors. Eur J Cell Biol 1995, 68:330-335.
64. Moore L, Fan D, Basu R, Kandalam V, Kassiri Z. Tissue inhibitor of metalloproteinases (TIMPs) in heart failure. Heart Fail Rev 2012, 17:693-706. 10.1007/s10741-011-9266-y, 21717224.
65. Spinale FG. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev 2007, 87:1285-1342. 10.1152/physrev.00012.2007, 17928585.
66. Mann DL, Spinale FG. Activation of matrix metalloproteinases in the failing human heart: breaking the tie that binds. Circulation 1998, 98:1699-1702. 10.1161/01.CIR.98.17.1699, 9788821.
67. Spinale FG, Wilbur NM. Matrix metalloproteinase therapy in heart failure. Curr Treat Options Cardiovasc Med 2009, 11:339-346. 10.1007/s11936-009-0034-4, 2745890, 19627666.
68. Kelly D, Khan S, Cockerill G, Ng LL, Thompson M, Samani NJ, Squire IB. Circulating stromelysin-1 (MMP-3): a novel predictor of LV dysfunction, remodelling and all-cause mortality after acute myocardial infarction. Eur J Heart Fail 2008, 10:133-139. 10.1016/j.ejheart.2007.12.009, 2635532, 18234553.
69. Ma Y, Chiao YA, Zhang J, Manicone AM, Jin YF, Lindsey ML. Matrix metalloproteinase-28 deletion amplifies inflammatory and extracellular matrix responses to cardiac aging. Microsc Microanal 2012, 18:81-90. 10.1017/S1431927611012220, 22153350.
70. Manso AM, Elsherif L, Kang SM, Ross RS. Integrins, membrane-type matrix metalloproteinases and ADAMs: potential implications for cardiac remodeling. Cardiovasc Res 2006, 69:574-584. 10.1016/j.cardiores.2005.09.004, 16253214.
71. Barbolina MV, Stack MS. Membrane type 1-matrix metalloproteinase: substrate diversity in pericellular proteolysis. Semin Cell Dev Biol 2008, 19:24-33. 10.1016/j.semcdb.2007.06.008, 2685078, 17702616.
72. Takino T, Saeki H, Miyamori H, Kudo T, Sato H. Inhibition of membrane-type 1 matrix metalloproteinase at cell-matrix adhesions. Cancer Res 2007, 67:11621-11629. 10.1158/0008-5472.CAN-07-5251, 18089791.
73. Shen XM, Wu YP, Feng YB, Luo ML, Du XL, Zhang Y, Cai Y, Xu X, Han YL, Zhang X, Zhan QM, Wang MR. Interaction of MT1-MMP and laminin-5γ2 chain correlates with metastasis and invasiveness in human esophageal squamous cell carcinoma. Clin Exp Metastasis 2007, 24:541-550. 10.1007/s10585-007-9091-9, 17668281.
74. Steffensen B, Wallon UM, Overall CM. Extracellular matrix binding properties of recombinant fibronectin type II-like modules of human 72-kDa gelatinase/type IV collagenase. High affinity binding to native type I collagen but not native type IV collagen. J Biol Chem 1995, 270:11555-11566. 10.1074/jbc.270.19.11555, 7744795.
75. Vincenti MP, Coon CI, Mengshol JA, Yocum S, Mitchell P, Brinckerhoff CE. Cloning of the gene for interstitial collagenase-3 (matrix metalloproteinase-13) from rabbit synovial fibroblasts: differential expression with collagenase-1 (matrix metalloproteinase-1). Biochem J 1998, 331(Pt 1):341-346. 1219357, 9512498.
76. Nuttall RK, Sampieri CL, Pennington CJ, Gill SE, Schultz GA, Edwards DR. Expression analysis of the entire MMP and TIMP gene families during mouse tissue development. FEBS Lett 2004, 563:129-134. 10.1016/S0014-5793(04)00281-9, 15063736.
77. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003, 92:827-839. 10.1161/01.RES.0000070112.80711.3D, 12730128.
78. Kandalam V, Basu R, Abraham T, Wang X, Soloway PD, Jaworski DM, Oudit GY, Kassiri Z. TIMP2 deficiency accelerates adverse post-myocardial infarction remodeling because of enhanced MT1-MMP activity despite lack of MMP2 activation. Circ Res 2010, 106:796-808. 10.1161/CIRCRESAHA.109.209189, 20056917.
79. Li YY, Feng Y, McTiernan CF, Pei W, Moravec CS, Wang P, Rosenblum W, Kormos RL, Feldman AM. Downregulation of matrix metalloproteinases and reduction in collagen damage in the failing human heart after support with left ventricular assist devices. Circulation 2001, 104:1147-1152. 10.1161/hc3501.095215, 11535571.
80. Heymans S, Schroen B, Vermeersch P, Milting H, Gao F, Kassner A, Gillijns H, Herijgers P, Flameng W, Carmeliet P, Van de Werf F, Pinto YM, Janssens S. Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart. Circulation 2005, 112:1136-1144. 10.1161/CIRCULATIONAHA.104.516963, 16103240.
81. Moore L, Fan D, Basu R, Kandalam V, Kassiri Z. Tissue inhibitor of metalloproteinases (TIMPs) in heart failure. Heart Fail Rev 2012, 17:693706.
82. Vanhoutte D, Heymans S. TIMPs and cardiac remodeling: 'Embracing the MMP-independent-side of the family'. J Mol Cell Cardiol 2010, 48:445-453. 10.1016/j.yjmcc.2009.09.013, 19799912.
83. Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol 2007, 8:221-233. 10.1038/nrm2125, 2760082, 17318226.
84. Shi Q, Liu X, Bai Y, Cui C, Li J, Li Y, Hu S, Wei Y. In vitro effects of pirfenidone on cardiac fibroblasts: proliferation, myofibroblast differentiation, migration and cytokine secretion. PLoS One 2011, 6:e28134. 10.1371/journal.pone.0028134, 3223242, 22132230.
85. Tyagi SC, Kumar SG, Banks J, Fortson W. Co-expression of tissue inhibitor and matrix metalloproteinase in myocardium. J Mol Cell Cardiol 1995, 27:2177-2189. 10.1016/S0022-2828(95)91443-9, 8576934.
86. Awad AE, Kandalam V, Chakrabarti S, Wang X, Penninger JM, Davidge ST, Oudit GY, Kassiri Z. Tumor necrosis factor induces matrix metalloproteinases in cardiomyocytes and cardiofibroblasts differentially via superoxide production in a PI3Kγ-dependent manner. Am J Physiol Cell Physiol 2010, 298:C679-C692. 10.1152/ajpcell.00351.2009, 20007453.
87. Deschamps AM, Spinale FG. Pathways of matrix metalloproteinase induction in heart failure: bioactive molecules and transcriptional regulation. Cardiovasc Res 2006, 69:666-676. 10.1016/j.cardiores.2005.10.004, 16426590.
88. Tsuruda T, Boerrigter G, Huntley BK, Noser JA, Cataliotti A, Costello-Boerrigter LC, Chen HH, Burnett JC. Brain natriuretic Peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ Res 2002, 91:1127-1134. 10.1161/01.RES.0000046234.73401.70, 12480813.
89. Sabeh F, Li XY, Saunders TL, Rowe RG, Weiss SJ. Secreted versus membrane-anchored collagenases: relative roles in fibroblast-dependent collagenolysis and invasion. J Biol Chem 2009, 284:23001-23011. 10.1074/jbc.M109.002808, 2755707, 19542530.
90. Zavadzkas JA, Mukherjee R, Rivers WT, Patel RK, Meyer EC, Black LE, McKinney RA, Oelsen JM, Stroud RE, Spinale FG. Direct regulation of membrane type 1 matrix metalloproteinase following myocardial infarction causes changes in survival, cardiac function, and remodeling. Am J Physiol Heart Circ Physiol 2011, 301:H1656-H1666. 10.1152/ajpheart.00141.2011, 21666120.
91. Spinale FG, Escobar GP, Mukherjee R, Zavadzkas JA, Saunders SM, Jeffords LB, Leone AM, Beck C, Bouges S, Stroud RE. Cardiac-restricted overexpression of membrane type-1 matrix metalloproteinase in mice: effects on myocardial remodeling with aging. Circ Heart Fail 2009, 2:351-360. 10.1161/CIRCHEARTFAILURE.108.844845, 2743030, 19808359.
92. Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 2000, 14:163-176. 316345, 10652271.
93. Bergman MR, Teerlink JR, Mahimkar R, Li L, Zhu BQ, Nguyen A, Dahi S, Karliner JS, Lovett DH. Cardiac matrix metalloproteinase-2 expression independently induces marked ventricular remodeling and systolic dysfunction. Am J Physiol Heart Circ Physiol 2007, 292:H1847-H1860.
94. Lovelock JD, Baker AH, Gao F, Dong JF, Bergeron AL, McPheat W, Sivasubramanian N, Mann DL. Heterogeneous effects of tissue inhibitors of matrix metalloproteinases on cardiac fibroblasts. Am J Physiol Heart Circ Physiol 2005, 288:H461-H468.
95. Diez J, Querejeta R, Lopez B, Gonzalez A, Larman M, Martinez Ubago JL. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 2002, 105:2512-2517. 10.1161/01.CIR.0000017264.66561.3D, 12034658.
96. Zannad F, Rossignol P, Iraqi W. Extracellular matrix fibrotic markers in heart failure. Heart Fail Rev 2010, 15:319-329. 10.1007/s10741-009-9143-0, 19404737.
97. Laviades C, Varo N, Fernandez J, Mayor G, Gil MJ, Monreal I, Diez J. Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation 1998, 98:535-540. 10.1161/01.CIR.98.6.535, 9714110.
98. Lindsay MM, Maxwell P, Dunn FG. TIMP-1: a marker of left ventricular diastolic dysfunction and fibrosis in hypertension. Hypertension 2002, 40:136-141. 10.1161/01.HYP.0000024573.17293.23, 12154103.
99. Querejeta R, Varo N, Lopez B, Larman M, Artinano E, Etayo JC, Martinez Ubago JL, Gutierrez-Stampa M, Emparanza JI, Gil MJ, Monreal I, Mindan JP, Diez J. Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation 2000, 101:1729-1735. 10.1161/01.CIR.101.14.1729, 10758057.
100. Lin YH, Chiu YW, Shiau YC, Yen RF, Tsai IJ, Ho YL, Huang PJ. The relation between serum level of amioterminal propeptide of type I procollagen and diastolic dysfunction in hypertensive patients without diabetes mellitus: a pilot study. J Hum Hypertens 2006, 20:964-967. 10.1038/sj.jhh.1002092, 17024136.
101. Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 2000, 102:2700-2706.
102. Lin YH, Ho YL, Wang TD, Liu CP, Kao HL, Chao CL, Chien KL, Hung CS, Wu VC, Tsai IJ, Yen RF, Shiau YC, Chen WJ. The relation of amino-terminal propeptide of type III procollagen and severity of coronary artery disease in patients without myocardial infarction or hibernation. Clin Biochem 2006, 39:861-866. 10.1016/j.clinbiochem.2006.05.017, 16919252.
103. Poulsen SH, Host NB, Jensen SE, Egstrup K. Relationship between serum amino-terminal propeptide of type III procollagen and changes of left ventricular function after acute myocardial infarction. Circulation 2000, 101:1527-1532. 10.1161/01.CIR.101.13.1527, 10747345.
104. Host NB, Jensen LT, Bendixen PM, Jensen SE, Koldkjaer OG, Simonsen EE. The aminoterminal propeptide of type III procollagen provides new information on prognosis after acute myocardial infarction. Am J Cardiol 1995, 76:869-873. 10.1016/S0002-9149(99)80251-3, 7484822.
105. Manhenke C, Orn S, Squire I, Radauceanu A, Alla F, Zannad F, Dickstein K. The prognostic value of circulating markers of collagen turnover after acute myocardial infarction. Int J Cardiol 2011, 150:277-282. 10.1016/j.ijcard.2010.04.034, 20493567.
106. Thomas CV, Coker ML, Zellner JL, Handy JR, Crumbley AJ, Spinale FG. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation 1998, 97:1708-1715. 10.1161/01.CIR.97.17.1708, 9591765.
107. Picard F, Brehm M, Fassbach M, Pelzer B, Scheuring S, Kury P, Strauer BE, Schwartzkopff B. Increased cardiac mRNA expression of matrix metalloproteinase-1 (MMP-1) and its inhibitor (TIMP-1) in DCM patients. Clin Res Cardiol 2006, 95:261-269. 10.1007/s00392-006-0373-z, 16598395.
108. Zervoudaki A, Economou E, Stefanadis C, Pitsavos C, Tsioufis K, Aggeli C, Vasiliadou K, Toutouza M, Toutouzas P. Plasma levels of active extracellular matrix metalloproteinases 2 and 9 in patients with essential hypertension before and after antihypertensive treatment. J Hum Hypertens 2003, 17:119-124. 10.1038/sj.jhh.1001518, 12574790.
109. Tziakas DN, Chalikias GK, Parissis JT, Hatzinikolaou EI, Papadopoulos ED, Tripsiannis GA, Papadopoulou EG, Tentes IK, Karas SM, Chatseras DI. Serum profiles of matrix metalloproteinases and their tissue inhibitor in patients with acute coronary syndromes. The effects of short-term atorvastatin administration. Int J Cardiol 2004, 94:269-277. 10.1016/j.ijcard.2003.05.013, 15093992.
110. Webb CS, Bonnema DD, Ahmed SH, Leonardi AH, McClure CD, Clark LL, Stroud RE, Corn WC, Finklea L, Zile MR, Spinale FG. Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling. Circulation 2006, 114:1020-1027. 10.1161/CIRCULATIONAHA.105.600353, 16923753.
111. Kelly D, Cockerill G, Ng LL, Thompson M, Khan S, Samani NJ, Squire IB. Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study. Eur Heart J 2007, 28:711-718. 10.1093/eurheartj/ehm003, 2202923, 17339265.
112. Wagner DR, Delagardelle C, Ernens I, Rouy D, Vaillant M, Beissel J. Matrix metalloproteinase-9 is a marker of heart failure after acute myocardial infarction. J Card Fail 2006, 12:66-72. 10.1016/j.cardfail.2005.08.002, 16500583.
113. Vandervelde S, van Amerongen MJ, Tio RA, Petersen AH, van Luyn MJ, Harmsen MC. Increased inflammatory response and neovascularization in reperfused vs. non-reperfused murine myocardial infarction. Cardiovasc Pathol 2006, 15:83-90. 10.1016/j.carpath.2005.10.006, 16533696.
114. Kobayashi K, Luo M, Zhang Y, Wilkes DC, Ge G, Grieskamp T, Yamada C, Liu TC, Huang G, Basson CT, Kisprt A, Geenspan DS, Sato TN. Secreted Frizzled-related protein 2 is a procollagen C proteinase enhancer with a role in fibrosis associated with myocardial infarction. Nat Cell Biol 2009, 11:46-55. 10.1038/ncb1811, 2722759, 19079247.
115. Duan J, Gherghe C, Liu D, Hamlett E, Srikantha L, Rodgers L, Regan JN, Rojas M, Willis M, Leask A, Majesky M, Deb A. Wnt1/betacatenin injury response activates the epicardium and cardiac fibroblasts to promote cardiac repair. EMBO J 2012, 31:429-442.
116. Jugdutt BI. Limiting fibrosis after myocardial infarction. N Engl J Med 2009, 360:1567-1569. 10.1056/NEJMcibr0810801, 19357414.
117. Van Lint P, Libert C. Matrix metalloproteinase-8: cleavage can be decisive. Cytokine Growth Factor Rev 2006, 17:217-223. 10.1016/j.cytogfr.2006.04.001, 16820317.
118. Cuadrado E, Ortega L, Hernandez-Guillamon M, Penalba A, Fernandez-Cadenas I, Rosell A, Montaner J. Tissue plasminogen activator (t-PA) promotes neutrophil degranulation and MMP-9 release. J Leukoc Biol 2008, 84:207-214. 10.1189/jlb.0907606, 18390930.
119. Matsuda A, Itoh Y, Koshikawa N, Akizawa T, Yana I, Seiki M. Clusterin, an abundant serum factor, is a possible negative regulator of MT6-MMP/MMP-25 produced by neutrophils. J Biol Chem 2003, 278:36350-36357. 10.1074/jbc.M301509200, 12860995.
120. Lambert JM, Lopez EF, Lindsey ML. Macrophage roles following myocardial infarction. Int J Cardiol 2008, 130:147-158. 10.1016/j.ijcard.2008.04.059, 2857604, 18656272.
121. Ammarguellat F, Larouche I, Schiffrin EL. Myocardial fibrosis in DOCA-salt hypertensive rats: effect of endothelin ET(A) receptor antagonism. Circulation 2001, 103:319-324. 10.1161/01.CIR.103.2.319, 11208696.
122. Ammarguellat FZ, Gannon PO, Amiri F, Schiffrin EL. Fibrosis, matrix metalloproteinases, and inflammation in the heart of DOCA-salt hypertensive rats: role of ET(A) receptors. Hypertension 2002, 39:679-684. 10.1161/hy0202.103481, 11882630.
123. Koitabashi N, Danner T, Zaiman AL, Pinto YM, Rowell J, Mankowski J, Zhang D, Nakamura T, Takimoto E, Kass DA. Pivotal role of cardiomyocyte TGF-beta signaling in the murine pathological response to sustained pressure overload. J Clin Invest 2011, 121:2301-2312. 10.1172/JCI44824, 3104748, 21537080.
124. Cao L, Gardner DG. Natriuretic peptides inhibit DNA synthesis in cardiac fibroblasts. Hypertension 1995, 25:227-234. 10.1161/01.HYP.25.2.227, 7843772.
125. Tsuruda T, Burnett JC. Adrenomedullin: an autocrine/paracrine factor for cardiorenal protection. Circ Res 2002, 90:625-627. 10.1161/01.RES.0000015462.11528.28, 11934826.
126. Kapoun AM, Liang F, O'Young G, Damm DL, Quon D, White RT, Munson K, Lam A, Schreiner GF, Protter AA. B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation. Circ Res 2004, 94:453-461. 10.1161/01.RES.0000117070.86556.9F, 14726474.
127. Watson CJ, Phelan D, Xu M, Collier P, Neary R, Smolenski A, Ledwidge M, McDonald K, Baugh J. Mechanical stretch up-regulates the B-type natriuretic peptide system in human cardiac fibroblasts: a possible defense against transforming growth factor-ss mediated fibrosis. Fibrogenesis Tissue Repair 2012, 5:9. 10.1186/1755-1536-5-9, 3411484, 22768849.
128. Knowles JW, Esposito G, Mao L, Hagaman JR, Fox JE, Smithies O, Rockman HA, Maeda N. Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice. J Clin Invest 2001, 107:975-984. 10.1172/JCI11273, 199554, 11306601.
129. Kishimoto I, Rossi K, Garbers DL. A genetic model provides evidence that the receptor for atrial natriuretic peptide (guanylyl cyclase-A) inhibits cardiac ventricular myocyte hypertrophy. Proc Natl Acad Sci U S A 2001, 98:2703-2706. 10.1073/pnas.051625598, 30202, 11226303.
130. Vellaichamy E, Khurana ML, Fink J, Pandey KN. Involvement of the NF-κB/matrix metalloproteinase pathway in cardiac fibrosis of mice lacking guanylyl cyclase/natriuretic peptide receptor A. J Biol Chem 2005, 280:19230-19242. 10.1074/jbc.M411373200, 15710627.
131. Morita E, Yasue H, Yoshimura M, Ogawa H, Jougasaki M, Matsumura T, Mukoyama M, Nakao K. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation 1993, 88:82-91. 10.1161/01.CIR.88.1.82, 8319360.
132. Saremi A, Gopal D, Maisel AS. Brain natriuretic peptide-guided therapy in the inpatient management of decompensated heart failure. Expert Rev Cardiovasc Ther 2012, 10:191-203. 10.1586/erc.11.188, 22292875.
133. Kandalam V, Basu R, Abraham T, Wang X, Awad A, Wang W, Lopaschuk GD, Maeda N, Oudit GY, Kassiri Z. Early activation of matrix metalloproteinases underlies the exacerbated systolic and diastolic dysfunction in mice lacking TIMP3 following myocardial infarction. Am J Physiol Heart Circ Physiol 2010, 299:H1012-H1023. 10.1152/ajpheart.00246.2010, 20675565.
134. Kandalam V, Basu R, Moore L, Fan D, Wang X, Jaworski DM, Oudit GY, Kassiri Z. Lack of tissue inhibitor of metalloproteinases 2 leads to exacerbated left ventricular dysfunction and adverse extracellular matrix remodeling in response to biomechanical stress. Circulation 2011, 124:2094-2105. 10.1161/CIRCULATIONAHA.111.030338, 21986284.
135. Thireau J, Karam S, Fauconnier J, Roberge S, Cassan C, Cazorla O, Aimond F, Lacampagne A, Babuty D, Richard S. Functional evidence for an active role of B-type natriuretic peptide in cardiac remodeling and pro-arrhythmogenicity. Cardiovasc Res 2012, 95:59-68. 10.1093/cvr/cvs167, 22617407.
136. Matsumura S, Iwanaga S, Mochizuki S, Okamoto H, Ogawa S, Okada Y. Targeted deletion or pharmacological inhibition of MMP-2 prevents cardiac rupture after myocardial infarction in mice. J Clin Invest 2005, 115:599-609. 548314, 15711638.
137. Lindsey ML, Escobar GP, Mukherjee R, Goshorn DK, Sheats NJ, Bruce JA, Mains IM, Hendrick JK, Hewett KW, Gourdie RG, Matisian LM, Spinale FG. Matrix metalloproteinase-7 affects connexin-43 levels, electrical conduction, and survival after myocardial infarction. Circulation 2006, 113:2919-2928. 10.1161/CIRCULATIONAHA.106.612960, 16769909.
138. Heymans S, Luttun A, Nuyens D, Theilmeier G, Creemers E, Moons L, Dyspersin GD, Cleutjens JP, Shipley M, Angellilo A, Levi M, Nube O, Aker A, Keshet E, Lupu F, Herbert JM, Smits JF, Shapio SD, Baes M, Borgers M, Collen D, Daemen MJ, Carmeliet P. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med 1999, 5:1135-1142. 10.1038/13459, 10502816.
139. Ducharme A, Frantz S, Aikawa M, Rabkin E, Lindsey M, Rohde LE, Schoen FJ, Kelly RA, Werb Z, Libby P, Lee RT. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest 2000, 106:55-62. 10.1172/JCI8768, 517910, 10880048.
140. Creemers EE, Davis JN, Parkhurst AM, Leenders P, Dowdy KB, Hapke E, Hauet AM, Escobar PG, Cleutjens JP, Smits JF, Daemen MJ, Zile MR, Spinale FG. Deficiency of TIMP-1 exacerbates LV remodeling after myocardial infarction in mice. Am J Physiol Heart Circ Physiol 2003, 284:H364-H371.
141. Koskivirta I, Kassiri Z, Rahkonen O, Kiviranta R, Oudit GY, McKee TD, Kyto V, Saraste A, Jokinen E, Liu PP, Vuoio E, Khokha R. Mice with tissue inhibitor of metalloproteinases 4 (Timp4) deletion succumb to induced myocardial infarction but not to cardiac pressure overload. J Biol Chem 2010, 285:24487-24493. 10.1074/jbc.M110.136820, 2915685, 20516072.
142. Glass C, Singla DK. Overexpression of TIMP-1 in embryonic stem cells attenuates adverse cardiac remodeling following myocardial infarction. Cell Transplant 2012, Epub ahead of print, PMID:22449760.
143. Jayasankar V, Woo YJ, Bish LT, Pirolli TJ, Berry MF, Burdick J, Bhalla RC, Sharma RV, Gardner TJ, Sweeney HL. Inhibition of matrix metalloproteinase activity by TIMP-1 gene transfer effectively treats ischemic cardiomyopathy. Circulation 2004, 110:II180-II186.
144. Ramani R, Nilles K, Gibson G, Burkhead B, Mathier M, McNamara D, McTiernan CF. Tissue inhibitor of metalloproteinase-2 gene delivery ameliorates postinfarction cardiac remodeling. Clin Transl Sci 2011, 4:24-31. 10.1111/j.1752-8062.2010.00252.x, 3079205, 21348952.
145. Matsusaka H, Ide T, Matsushima S, Ikeuchi M, Kubota T, Sunagawa K, Kinugawa S, Tsutsui H. Targeted deletion of matrix metalloproteinase 2 ameliorates myocardial remodeling in mice with chronic pressure overload. Hypertension 2006, 47:711-717. 10.1161/01.HYP.0000208840.30778.00, 16505197.
146. Heymans S, Lupu F, Terclavers S, Vanwetswinkel B, Herbert JM, Baker A, Collen D, Carmeliet P, Moons L. Loss or inhibition of uPA or MMP-9 attenuates LV remodeling and dysfunction after acute pressure overload in mice. Am J Pathol 2005, 166:15-25. 10.1016/S0002-9440(10)62228-6, 1602291, 15631996.
147. Kassiri Z, Oudit GY, Sanchez O, Dawood F, Mohammed FF, Nuttall RK, Edwards DR, Liu PP, Backx PH, Khokha R. Combination of tumor necrosis factor-alpha ablation and matrix metalloproteinase inhibition prevents heart failure after pressure overload in tissue inhibitor of metalloproteinase-3 knock-out mice. Circ Res 2005, 97:380-390. 10.1161/01.RES.0000178789.16929.cf, 16037568.
148. Kassiri Z, Defamie V, Hariri M, Oudit GY, Anthwal S, Dawood F, Liu P, Khokha R. Simultaneous transforming growth factor beta-tumor necrosis factor activation and cross-talk cause aberrant remodeling response and myocardial fibrosis in Timp3-deficient heart. J Biol Chem 2009, 284:29893-29904. 10.1074/jbc.M109.028449, 2785619, 19625257.